paclitaxel has been researched along with Cancer of the Fallopian Tube in 156 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (4.49) | 18.2507 |
| 2000's | 51 (32.69) | 29.6817 |
| 2010's | 82 (52.56) | 24.3611 |
| 2020's | 16 (10.26) | 2.80 |
| Authors | Studies |
|---|---|
| Aoki, D; Chiyoda, T; Hirasawa, A; Iwasa-Inoue, N; Kataoka, F; Kobayashi, Y; Morisada, T; Nanki, Y; Nomura, H; Sakai, K; Yamagami, W; Yoshihama, T | 1 |
| Bixel, K; Brady, MF; Burger, RA; Casey, AC; Cosgrove, C; duPont, NC; Enserro, D; Fujiwara, K; Monk, BJ; Moxley, K; Rubin, S; Soper, J; Tewari, KS; Thaker, P; Wahner Hendrickson, AE; Walker, JL | 1 |
| Benjamin, L; Corr, BR; Culm-Merdek, K; Fu, S; Hamilton, EP; Mockbee, C; Moore, KN; Naumann, RW; Rosengarten, RD; Stagg, R; Wenham, RM; Youssoufian, H | 1 |
| Bohart, RD; Goldstein, BH; Micha, JP; Rettenmaier, MA | 1 |
| Jimi, T; Kaneda, M; Kitai, M; Matsuoka, K; Nagao, S; Shibutani, T; Shiozaki, T; Sudo, T; Suzuki, K; Yamaguchi, S; Yamamoto, K; Yano, H | 1 |
| Aghajanian, C; Armstrong, DK; Bell-McGuinn, KM; Chen, A; Duska, LR; Fracasso, PM; Gordon, S; Gray, HJ; Guntupalli, SR; Hagemann, AR; Mathews, CA; Miller, A; Moore, KN; O'Cearbhaill, RE; O'Malley, D; Schilder, RJ; Walker, JL | 1 |
| Iida, Y; Odajima, S; Okamoto, A; Saito, M; Tabata, J; Ueda, K; Yamada, K; Yanaihara, N; Yokomizo, R | 1 |
| Chang, HK; Chang, SJ; Han, SS; Kim, DY; Kim, HS; Kim, J; Kim, S; Lee, JW; Lee, KH; Park, SJ; Park, SY; Shim, SH | 1 |
| Burger, R; Coleman, RL; Handley, KF; Molin, GZD; Moore, KN; Sood, AK; Stagg, R | 1 |
| Chang, SJ; Ji, YI; Kim, HS; Kim, JW; Kim, SY; Kwon, SH; Lee, EJ; Lee, M; Lee, SH; Lee, SJ; Park, S; Park, SJ; Roh, JW; Shim, SH; Song, T | 1 |
| Chen, ZP; Jiang, J; Ni, C; Qian, XL; Zhang, M; Zhang, YQ; Zhu, HP; Zuo, Y | 1 |
| Aghajanian, C; Banerjee, S; Berger, R; Boyd, AP; Christy-Bittel, J; Churruca, C; Cibula, D; Clamp, A; Coleman, RL; Colombo, N; Del Campo, JM; Drill, E; Grisham, RN; Hilpert, F; Kalbacher, E; Kristensen, G; Marth, C; Mirza, MR; Monk, BJ; Moore, KN; O'Malley, DM; Oehler, MK; Oza, AM; Pignata, S; Ray-Coquard, I; Romero, I; Sehouli, J; Vergote, I; Vuylsteke, P; Westermann, A | 1 |
| Chosokabe, M; Deura, I; Kawamoto, H; Koike, J; Kondo, H; Kuji, S; Maeda, I; Migita, O; Ohara, T; Suzuki, N; Tozawa-Ono, A; Tsugawa, K | 1 |
| Elit, L; Ethier, JL; Hirte, H; May, T; Petz, L; Poon, R; Speakman, J; Yao, X | 1 |
| Backes, FJ; Bixel, K; Chen, M; Cohn, DE; Copeland, LJ; Cosgrove, C; Dzwigalski, K; Fowler, JM; Hays, J; Hill, K; O'Malley, D; Phelps, M; Poi, M; Salani, R; Wei, L | 1 |
| Ikeda, T; Kaneda, M; Kondo, E; Maki, S; Nii, M; Nimura, R; Tabata, T; Yoshida, K | 1 |
| Armstrong, DK; Ashfaq, R; Basen-Engquist, K; Brady, MF; Chan, JK; Coleman, RL; Davidson, SA; DiSilvestro, P; Fujiwara, K; Herzog, TJ; Huang, H; Kim, BG; Mannel, RS; O'Malley, DM; Rubin, SC; Sabbatini, P; Spirtos, NM; Tewari, KS; Walker, JL | 1 |
| Bulsara, M; Codde, J; Coghlan, E; Cohen, PA; Koay, MHE; Leung, Y; MaGee, D; Meniawy, TM; Mohan, GR; Munro, A; Nichols, CB; Salfinger, SG; Stewart, CJ; Tan, A; Tan, J | 1 |
| Celebi, K; Kaban, A; Saip, P; Salihoglu, Y; Sozen, H; Topuz, S | 1 |
| Aoki, D; Hashimoto, S; Hirano, T; Hirasawa, A; Iwasa, N; Kataoka, F; Makabe, T; Nanki, Y; Nomura, H; Sakai, K; Yamagami, W; Yoshihama, T | 1 |
| Bun, S; Ebata, T; Fujiwara, Y; Kato, T; Kodaira, M; Shimizu, C; Shimoi, T; Shimomura, A; Tamura, K; Yonemori, K; Yoshida, H; Yunokawa, M | 1 |
| Mandai, M; Matsumura, N; Murakami, K; Nakai, H; Suzuki, A; Takaya, H; Tobiume, T | 1 |
| Becker, DA; Bevis, KS; Leath, CA; Smith, BQ; Walters-Haygood, CL | 1 |
| Kruitwagen, RF; Lalisang, RI; Sonke, GS; Timmermans, M; Van de Vijver, KK; van der Aa, MA; Witteveen, PO | 1 |
| Begum, S; Jakes, A; Lane, G; Mehra, G; Nath, R; Polson, A; Rajkumar, S; Sayasneh, A | 1 |
| Aghajanian, C; Bonebrake, AJ; Dewdney, SB; Johnston, CM; Kauderer, JT; Monk, BJ; Moxley, KM; Secord, AA; Ueland, FR | 1 |
| Aghajanian, C; Bender, DP; Carlson, JW; Crane, EK; Darus, CJ; Makker, V; Mannel, RS; Matulonis, UA; Mutch, DG; Sill, MW | 1 |
| Bakrin, N; Gladieff, L | 1 |
| Akladios, C; Alfonsi, P; Bakrin, N; Ballester, M; Bendifallah, S; Bolze, PA; Bonnet, F; Bourgin, C; Chabbert-Buffet, N; Collinet, P; Courbiere, B; Daraï, E; De la Motte Rouge, T; Devouassoux-Shisheboran, M; Falandry, C; Ferron, G; Fournier, L; Gladieff, L; Golfier, F; Gouy, S; Guyon, F; Huchon, C; Lambaudie, E; Lavoue, V; Leary, A; Leblanc, E; Lecuru, F; Lefrere-Belda, MA; Lemoine, A; Narducci, F; Ouldamer, L; Pautier, P; Planchamp, F; Pouget, N; Ray-Coquard, I; Rousset-Jablonski, C; Senechal-Davin, C; Thomassin-Naggara, I; Touboul, C; Uzan, C; You, B | 1 |
| Bamias, A; Colombo, N; Covens, A; Del Campo, JM; Kroep, JR; Ma, H; Marth, C; Meier, W; Monk, BJ; O'Malley, DM; Park, SY; Pickett, CA; Raza Mirza, M; Scambia, G; Van Calster, B; Vergote, I; Wenham, RM | 1 |
| Blaakaer, J; Christiansen, T; Iversen, LH; Mikkelsen, MS; Petersen, LK | 1 |
| Armstrong, DK; Coleman, RL; Phillips, M; Weil, SC; White, AJ | 1 |
| Apte, SM; Bou Zgheib, N; Gonzalez-Bosquet, J; Judson, PL; Lancaster, JM; Roberts, WS; Teefey, P; Wenham, RM | 1 |
| Abaid, LN; Brown, JV; Goldstein, BH; Lopez, KL; Mendivil, AA; Micha, JP; Rettenmaier, MA | 2 |
| Khemapech, N; Lertkhachonsuk, R; Oranratanaphan, S; Termrungruanglert, W; Vasurattana, A | 1 |
| Dhillon, S | 1 |
| Bookman, MA; Brady, MF; Burger, RA; Kong, G; Nguyen, HP; Rhee, J; Sovak, MA | 1 |
| Aoki, D; Isonishi, S; Jobo, T; Katsumata, N; Kimura, E; Kodama, S; Michimae, H; Ochiai, K; Sugiyama, T; Takahashi, F; Terauchi, F; Yasuda, M | 1 |
| Bae, DS; Choi, CH; Kim, BG; Kim, HJ; Kim, MK; Kim, TJ; Lee, JW; Lee, YY; Park, JY; Yoon, A | 1 |
| Awtrey, CS; Battelli, C; Buss, MK; Campo, M; Konstantinopoulos, PA | 1 |
| Dowlati, A; Eaton, S; Frasure, H; Fu, P; Fusco, N; Schwandt, A; von Gruenigen, VE; Waggoner, S; Wenham, RM; Wright, JJ | 1 |
| Cheewakriangkrai, C; Khunamornpong, S; Kietpeerakool, C; Phongsaranantakul, S; Sribanditmongkol, N; Srisomboon, J | 1 |
| Banerjee, S; Clamp, A; Dawson-Athey, L; Earl, H; Feeney, A; Hall, G; Hall, M; James, L; Kaye, SB; Khan, I; Kristeleit, R; Lawrence, C; Ledermann, JA; McNeish, IA; Persic, M; Raja, F; Webber, L | 1 |
| Andrade, C; Clark, RM; del Carmen, MG; Esselen, KM; Foley, OW; Hinchcliff, EM; Horowitz, NS; Rauh-Hain, JA; Vargas, RJ; Winograd, D | 1 |
| Katsumata, N | 1 |
| Böhm, S; Brockbank, E; Cook, LS; Dowe, T; Ennis, D; Faruqi, A; Fitzpatrick, A; Gilks, CB; Jeyarajah, A; Le, ND; Lockley, M; Said, I; Santos, JL; Singh, N; Tinker, AV | 1 |
| Beijnen, JH; Harms, E; Marchetti, S; Mergui-Roelvink, MW; Rehorst, H; Schellens, JH; Sonke, GS; Steeghs, N; van der Noll, R | 1 |
| Alexander, H; Banerjee, S; Barton, D; Bodla, S; Georgiou, A; Gore, M; Kaye, S; McLachlan, J; Nobbenhuis, M; Seifert, H | 1 |
| Burger, RA; Cohn, DE; Duska, LR; Java, JJ | 1 |
| Fernandez, RO; Iniesta, MD; Lu, KH; Malpica, A; Patrono, MG; Ramirez, PT; Salvo, G | 1 |
| Bidziński, M; Bjørge, L; Colombo, N; de Gregorio, N; Del Campo, JM; Denison, U; du Bois, A; Harter, P; Heubner, M; Hilpert, F; Kristensen, G; Lortholary, A; Malander, S; Meier, W; Merger, M; Minarik, T; Mirza, MR; Nicoletto, MO; Ottevanger, P; Pfisterer, J; Pignata, S; Ray-Coquard, I; Reuss, A; Sailer, MO; Scambia, G; Sevin, E; Vergote, I | 1 |
| Chaithongwongwatthana, S; Yanaranop, M | 1 |
| Alpert, Y; Bruchim, I; Fishman, A; Piura, E; Sade, D; Weeg, N | 1 |
| Chang, WP; Chang, Y; Chang, YH; Chuang, CM; Lee, WH; Lu, CH; Yen, MS | 1 |
| Akkar, OB; Karadayi, K; Karakus, S; Kurt, A; Ugurlu, GP; Yanik, A; Yildiz, C | 1 |
| Chi, DS; Gardner, GJ; Long Roche, K; Mueller, JJ; O'Cearbhaill, RE; Schlappe, BA; Sonoda, Y; Zivanovic, O | 1 |
| Aviki, E; Berkowitz, R; Clark Sisodia, R; Davis, M; Del Carmen, M; Horowitz, N; Muto, M; Rauh-Hain, JA; Schorge, J; Worley, M | 1 |
| Kamura, T; Kasamatsu, T; Kawana, K; Kobayashi, H; Konishi, I; Nakamura, K; Nakanishi, T; Onda, T; Saito, M; Saito, T; Satoh, T; Takano, M; Takehara, K; Takeshima, N; Ushijima, K; Wakabayashi, M; Watanabe, Y; Yaegashi, N; Yokota, H; Yoshikawa, H | 1 |
| Bun, S; Ebata, T; Fujiwara, Y; Hayashi, Y; Kato, T; Kodaira, M; Makino, Y; Shimizu, C; Shimoi, T; Shimomura, A; Tamura, K; Yonemori, K; Yunokawa, M | 1 |
| Bamias, A; Chmielowska, E; Colombo, N; Davidenko, I; DeCensi, A; Gadducci, A; González-Martín, A; Hegg, R; Joly, F; Korach, J; Martin, N; Mendiola, C; Oza, AM; Pautier, P; Robb, S; Selle, F; Zamagni, C; Zvirbule, Z | 1 |
| Bun, S; Ebata, T; Fujiwara, Y; Kato, T; Kodaira, M; Shimizu, C; Shimoi, T; Shimomura, A; Tamura, K; Yonemori, K; Yunokawa, M | 1 |
| Lengyel, E; Onujiogu, N; Yamada, SD | 1 |
| Aghajanian, CA; DeRosa, FA; Gerst, SR; Hensley, ML; Konner, J; Sabbatini, PJ; Schilder, RJ; Spriggs, DR; Tew, WP | 1 |
| Aragon-Ching, JB; Dahut, WL; Desai, N; Figg, WD; Gardner, ER; Hawkins, MJ; Jones, J; Scripture, CD; Sparreboom, A | 1 |
| Aikins, JK; Allievi, C; Bookman, MA; Darcy, KM; DeGeest, K; Egorin, MJ; Mannel, RS; Morgan, MA; Rose, PG; Sill, MW | 1 |
| Bamias, A; Bozas, G; Dimopoulos, MA; Grimani, I; Lainakis, G; Lianos, E; Papadimitriou, CA; Peitsidis, P; Rodolakis, A; Vlahos, G | 1 |
| Adler, L; O'Malley, D; Sabbatini, P; Secord, AA; Sill, MW | 1 |
| Itamochi, H; Kanamori, Y; Kawaguchi, W; Kigawa, J; Oishi, T; Sato, S; Shimada, M; Terakawa, N | 1 |
| Atkinson, T; Horowitz, NS; Krag, KJ; Krasner, CN; Lee, H; Matulonis, UA; Penson, RT | 1 |
| Alberts, DS; Liu, PY; Markman, M; Robinson, WR; Smith, HO; Tiersten, AD; Wilczynski, SP | 1 |
| Fukuda, H; Hatae, M; Iwasaka, T; Kamura, T; Kobayashi, H; Konishi, I; Nakanishi, T; Onda, T; Shibata, T; Yoshikawa, H | 1 |
| Alvarez, RD; Berry, E; Buttin, BM; Lurain, JR; Matthews, KS; Schink, J; Singh, DK | 1 |
| Asmar, L; Boehm, KA; Crozier, M; Encarnacion, C; Hancock, K; Messing, MJ; Teneriello, MG; Tseng, PC; Williams, A | 1 |
| Argenta, PA; Geller, M; Ivy, JJ; Jonson, AL; Pierson, SM | 1 |
| Andreadis, C; Aravantinos, G; Economopoulos, T; Fountzilas, G; Macheras, A; Papatsibas, G; Papaxoinis, G; Pectasides, D; Pectasides, E; Pliarchopoulou, K | 1 |
| Eno, ML; Im, DD; Matsuo, K; Rosenshein, NB; Sood, AK | 1 |
| Groe, R; Grothey, A; Kantelhardt, EJ; Kegel, T; Koelbl, H; Mueller, LP; Schmoll, HJ; Seliger, G; Strauss, HG; Thomssen, C | 1 |
| Bougnoux, P; Carrasco, AT; Fumoleau, P; Joly, F; Kerbrat, P; Lhommé, C; Pautier, P; Petit, T; Ringeisen, F; Rixe, O | 1 |
| Fracasso, PM; Garcia, AA; Knight, D; Mannel, RS; Muggia, F; Sill, MW; Swensen, R; Tiersten, AD; Warshal, DP | 1 |
| Adamus, G; Bodurka, DC; Liu, J; Raghunath, A; Schiffman, JS | 1 |
| Blank, SV; Chen, HX; Christos, P; Curtin, JP; Goldman, N; Liebes, L; Muggia, FM; Runowicz, CD; Sparano, JA | 1 |
| Ahn, EH; Eno, ML; Im, DD; Matsuo, K; Rosenshein, NB; Shahzad, MM; Sood, AK | 1 |
| Aoki, D; Aotani, E; Fujiwara, K; Hamano, T; Katsumata, N; Kigawa, J; Nagao, S; Sugiyama, T; Suzuki, M; Takeuchi, M; Yoshikawa, H | 1 |
| Clamp, AR; Evans, S; Griffiths, RW; Hasan, J; Jayson, GC; Kumaran, GC; Mitchell, CL; Welch, RS; Zee, YK | 1 |
| Ishikawa, M; Komiyama, M; Komiyama, S; Kurahashi, T; Mikami, M; Tanaka, K; Udagawa, Y | 1 |
| Coleman, RL; Degeest, K; Fujiwara, K; Greer, B; Mannel, RS; Morgan, MA; Rubin, SC; Sill, MW; Waggoner, S; Walker, JL; Yamada, SD | 1 |
| Arimoto, T; Kawana, K; Nakagawa, S; Oda, K; Taketani, Y; Yasugi, T | 1 |
| Azodi, M; Baker, L; Husband, A; Kelly, MG; Mor, G; O'Malley, DM; Rutherford, TJ; Schwartz, PE | 1 |
| Abaid, LN; Brown, JV; Goldstein, BH; Lopez, KL; Micha, JP; Rettenmaier, MA | 1 |
| Brady, WE; Coleman, RL; Hoffman, JS; Lentz, SS; McMeekin, DS; Rose, PG; Shahin, MS; Soper, JT | 1 |
| Hwang, JH; Lee, JK; Lee, KW; Lee, NW; Shin, BK; Song, SH | 1 |
| Hyde, J; Landrum, LM; Mannel, RS; McMeekin, DS; Moore, KN; Walker, JL | 1 |
| Changchien, CC; Huang, CC; Huang, HY; Lin, H; Ou, YC; Tseng, CW | 1 |
| Debernardo, RL; Dizon, DS; Duska, LR; Eisenhauer, EL; Fracasso, PM; Gould, N; Mannel, RS; Rubin, SC; Sill, MW; Yamada, SD | 1 |
| Griffin, CL; Hirte, H; Ledermann, JA; Parmar, MK; Qian, W; Raja, FA; Swart, AM | 1 |
| Burkholder, TL; Chen, MD; Gill, JF; Gordon, AN; Hines, J; Homesley, HD; Janicek, MF; Lim, PC; McMeekin, S; Obasaju, CK; Orlando, M; Tai, DF; Teneriello, M; Vaccarello, L; Wang, Y; Zhao, L | 1 |
| Ota, T; Takeshima, N; Takizawa, K | 1 |
| Fujiwara, K; Goto, T; Hasegawa, K; Iwasa, N; Kurosaki, A; Nagao, S; Nishikawa, T; Ohishi, R | 1 |
| Armstrong, DK; Disilvestro, P; Fracasso, PM; Gould, N; Huang, H; Mannel, RS; Sill, MW; Thaker, PH; Waggoner, S; Walker, JL; Wenzel, L; Yamada, SD | 1 |
| Brown, JV; Buck, M; Chambers, SK; Covens, A; Davy, M; Ghatage, P; Hansen, VL; Karlan, BY; Leath, CA; Nagarkar, RV; Nguyen, H; Oza, AM; Pippitt, CH; Provencher, DM; Richardson, GE; Stepan, DE; Sun, YN; Tassoudji, M; Vergote, IB; Weinreich, DM | 1 |
| Itamochi, H; Kigawa, J; Kitada, F; Minagawa, Y; Okada, M; Sato, S; Shimada, M | 1 |
| Abu Shahin, N; Alberts, DS; Chambers, SK; Chow, HH; Clouser, MC; Cohen, JL; Cragun, JM; Cui, H; Hatch, KD; Janicek, MF; Laughren, C; Wright, HM | 1 |
| Gallagher, CJ; Jeyarajah, A; Ledermann, JA; McCormack, M; McDonald, N; McNeish, I; Mould, T; Olaitan, A; Oram, D; Orphanos, G; Reynolds, K; Saha, A; Shepherd, J; Varughese, M; Wilson, P | 1 |
| Gawrychowski, K; Jeske, W; Smiertka, W | 1 |
| Aghajanian, C; Barlin, JN; Bell-McGuinn, KM; Bou Zgheib, N; Chi, DS; Dao, F; Ferguson, SE; Hensley, ML; Konner, J; Sabbatini, PJ; Tew, WP | 1 |
| Bristow, RE; Chang, SJ; Ryu, HS | 1 |
| Campos, S; Esselen, KM; Growdon, W; Horowitz, NS; Krasner, C; Rodriguez, N | 1 |
| Ho, ES; Hsu, ST; Ke, YM; Lu, CH; Tsai, CP; Wang, RC | 1 |
| Armstrong, DK; DiSilvestro, PA; Fracasso, PM; Gould, N; Mannel, RS; Sill, MW; Thaker, PH; Waggoner, SE; Walker, JL; Yamada, SD | 1 |
| Boaz, M; Golan, A; Levy, T; Menczer, J; Shem, EB; Weiser, R | 1 |
| Antsaklis, A; Bamia, C; Bamias, A; Dimopoulos, MA; Haidopoulos, D; Kakoyianni, K; Kostouros, E; Rodolakis, A; Thomakos, N; Vlahos, G; Zagouri, F | 1 |
| Chu, P; Ghatage, P; Glaze, S; Nation, J; Nelson, G; Teitelbaum, L | 1 |
| Bamba, M; Fujimoto, Y; Kaneko, C; Kobayashi, TK; Moritani, S; Urabe, M | 1 |
| Alberts, DS; Glass, T; Goodwin, JW; Hatch, KD; Markman, M; Smith, HO; Taylor, SA; Weiss, GR | 1 |
| Alberts, D; Alvarez, RD; Copeland, LJ; Jiang, C; Liu, PY; Markman, M; Monk, B; Wilczynski, S | 1 |
| Belinson, J; Kulp, B; Markman, M; Peterson, G; Webster, K; Zanotti, K | 2 |
| Bilezikci, B; Demirhan, B; Erkanli, S; Haberal, A; Kuscu, E; Oktem, M | 1 |
| Belinson, J; Escobar, PF; Markman, M; Rose, P; Webster, K; Zanotti, K | 1 |
| A'Hern, R; Cole, C; Everard, M; Gibbens, I; Gore, M; Hall, G; Harries, M; Jenkins, A; Kaye, S; Moss, C; Perren, T; Pizzada, O; Shah, R | 1 |
| Birk, CL; Brown, JV; Goldstein, BH; Graham, C; Mattison, J; Micha, JP; Rettenmaier, MA | 1 |
| Aghajanian, C; Anderson, S; Brown, JV; Dizon, D; Dupont, J; Eisenfeld, AJ; Jacobs, A; Mehdi, A; Peters, WA; Rivkin, S; Sabbatini, P; Spriggs, D | 1 |
| Kietpeerakool, C; Srisomboon, J; Suprasert, P | 1 |
| Asai, S; Dokoh, J; Ishikawa, M; Komiyama, S; Mikami, M; Tsuji, H | 1 |
| Acikalin, MF; Ozalp, S; Peker, B; Yalcin, OT | 1 |
| Carvalho, FM; Carvalho, JP; Feher, O; Maluf, FC; Schütz, FA | 1 |
| Horowitz, NS; Krasner, CN; Lee, SI; Oliva, E; Roche, M; Supko, JG | 1 |
| Campos, S; Duska, LR; Falke, R; Krasner, CN; Lee, H; Matulonis, UA; Penson, RT; Roche, M; Seiden, MV; Smith, LM | 1 |
| Altundag, OB; Gungor, T; Mollamahmutoglu, L; Ustunyurt, E | 1 |
| Fusco, N; Greer, BE; Horowitz, IR; Markman, M; Rose, PG | 1 |
| Boggess, JF; Brady, MF; Burger, RA; Clarke-Pearson, DL; Hanly, M; Lee, RB; Mannel, R; Spriggs, DR; Vaccarello, L | 1 |
| Aydin, Y; Cicin, I; Eralp, Y; Ozluk, Y; Saip, P; Selam, M; Topuz, E; Topuz, S | 1 |
| Fukuda, H; Kamura, T; Konishi, I; Matsumoto, K; Onda, T; Sato, A; Shibata, T; Yoshikawa, H | 1 |
| Fang, SH; Gao, YL; Yu, AJ | 1 |
| Edwards, CL; Fromm, GL; Kavanagh, JJ; Kudelka, AP; Mante, R; Tresukosol, D | 1 |
| Cai, S; Fan, J; Tang, J | 1 |
| Francis, P; Hakes, T; Hoskins, W; Markman, M; Rowinsky, E; Schneider, J | 1 |
| Loizzi, P; Nappi, L; Nappi, R; Resta, L | 1 |
| Belinson, J; Fluellen, L; Fusco, N; Horowitz, IR; Jones, E; Kennedy, A; Kulp, B; Markman, M; McGuire, WP; Peterson, G; Rose, PG; Webster, K | 1 |
| Brady, MF; Hanjani, P; Markman, M; Rubin, SC; Spirtos, NM | 1 |
| Belinson, J; Hurteau, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Sutton, G; Webster, K | 1 |
| Atkinson, EN; Guedes, Ed; Kavanagh, JJ; Kudelka, AP; Nelson-Taylor, T; Rogers, R; Sittisomwong, T; Steger, M; Verschraegen, CF; Vincent, M | 1 |
| Fowler, JM; Greer, BE; Horowitz, IR; McGuire, WP; Rodriguez, M; Rose, PG; Waggoner, S | 1 |
| Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K | 3 |
| Barakat, RR; Cohen, R; Gemignani, ML; Hensley, ML; Saigo, PE; Venkatraman, E | 1 |
| Adolph, A; Biem, S; Khan, K; Le, T | 1 |
| Allen, D; Davison, J; Gates, P; Neesham, D; Planner, R; Prince, HM; Quinn, M; Rischin, D | 1 |
| Cormio, G | 1 |
| Shao, H | 1 |
| Gadducci, A | 1 |
| Newton, HB; Santi, M; Stevens, C | 1 |
| Allen, M; Gibbs, DD; Gore, ME; Johnston, SR; Pyle, L; Vaughan, M; Webb, A | 1 |
| Buekers, T; Buller, RE; Horowitz, JA; Karlan, BY; Kreienberg, R; Pegram, M; Petrauskas, S; Runnebaum, IB; Shahin, M; Slamon, D | 1 |
9 review(s) available for paclitaxel and Cancer of the Fallopian Tube
| Article | Year |
|---|---|
Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Quality of Life | 2021 |
[Malignant epithelial ovarian cancer: Role of intra peritoneal chemotherapy and hyperthermic intra peritoneal chemotherapy (HIPEC): Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian can
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Fallopian Tube Neoplasms; Female; France; Humans; Hyperthermia, Induced; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quality of Life; Societies, Medical | 2019 |
Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Topics: Adult; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Evidence-Based Medicine; Fallopian Tube Neoplasms; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A | 2013 |
Dose-dense approaches to ovarian cancer treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis | 2015 |
Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): A comprehensive review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma in Situ; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Humans; Incidence; Mutation; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Platinum Compounds; Salpingectomy | 2015 |
Primary clear cell carcinoma of a paratubal cyst: a case report with literature review.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Fallopian Tube Neoplasms; Female; Humans; Keratins; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Parovarian Cyst; Salpingectomy | 2011 |
Management of advanced-stage primary carcinoma of the fallopian tube: case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta, Thoracic; Appendectomy; Cisplatin; Cystadenocarcinoma, Serous; Diagnosis, Differential; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Hysterectomy; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Omentum; Ovariectomy; Paclitaxel; Pelvic Neoplasms; Second-Look Surgery | 2003 |
Mixed serous and endometrioid carcinoma of the fallopian tube: a case report with literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Cyclophosphamide; Cystadenocarcinoma, Serous; Fallopian Tube Neoplasms; Female; Gynecologic Surgical Procedures; Humans; Mixed Tumor, Malignant; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2005 |
Current management of fallopian tube carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Ovariectomy; Paclitaxel | 2002 |
78 trial(s) available for paclitaxel and Cancer of the Fallopian Tube
| Article | Year |
|---|---|
Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.
Topics: Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Asian; Bevacizumab; Black or African American; Carboplatin; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Ethnicity; Fallopian Tube Neoplasms; Female; Hispanic or Latino; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Proportional Hazards Models; Survival Rate; White People | 2022 |
Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.
Topics: Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Female; Humans; Ovarian Neoplasms; Paclitaxel; Platinum; Retrospective Studies; RNA; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2022 |
A phase II, open-label, non-randomized, prospective study assessing paclitaxel, carboplatin and metformin in the treatment of advanced stage ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Female; Humans; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies | 2023 |
A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Progression-Free Survival | 2020 |
Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Progression-Free Survival; Survival Analysis | 2020 |
Reduction of cycles of neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian or primary peritoneal cancer (ROCOCO): study protocol for a phase III randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Case-Control Studies; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Survival Rate; Young Adult | 2020 |
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
Topics: Adult; Aged; Benzimidazoles; Cystadenocarcinoma, Serous; Doxorubicin; Fallopian Tube Neoplasms; Female; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols; Progression-Free Survival; Protein Kinase Inhibitors; Topotecan; Young Adult | 2020 |
Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Genital Neoplasms, Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Quinolines | 2021 |
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Young Adult | 2017 |
Utilization of an Alternative Docetaxel-based Intraperitoneal Chemotherapy Regimen in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma: A Continued Need for Ovarian Cancer Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2019 |
A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Fallopian Tube Neoplasms; Female; Humans; Hydrazines; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2018 |
A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Protein Kinase Inhibitors; Pyridines | 2019 |
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Double-Blind Method; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Recombinant Fusion Proteins; Salvage Therapy; Survival Rate | 2019 |
Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Drug Hypersensitivity; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2013 |
A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Consolidation Chemotherapy; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Intention to Treat Analysis; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Severity of Illness Index; Survival Analysis | 2013 |
Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Neoplasms, Glandular and Epithelial; Observer Variation; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Radiography; Single-Blind Method | 2013 |
Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Proportional Hazards Models | 2013 |
Safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy-induced nausea and vomiting in patients with ovarian cancer treated with paclitaxel/carboplatin.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Benzimidazoles; Carboplatin; Dexamethasone; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Morpholines; Nausea; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Vomiting; Young Adult | 2014 |
Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Niacinamide; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Sorafenib | 2014 |
A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Disease-Free Survival; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Quinazolines; Retroperitoneal Neoplasms | 2014 |
Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Disease Progression; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Salvage Therapy; Treatment Failure | 2015 |
Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236).
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Bevacizumab; Body Mass Index; CA-125 Antigen; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Double-Blind Method; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Obesity; Ovarian Neoplasms; Paclitaxel; Patient Readmission; Peritoneal Neoplasms; Risk Factors; Time Factors | 2015 |
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cytoreduction Surgical Procedures; Diarrhea; Disease Progression; Disease-Free Survival; Double-Blind Method; Fallopian Tube Neoplasms; Female; Humans; Indoles; Intention to Treat Analysis; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Response Evaluation Criteria in Solid Tumors; Thrombocytopenia; Young Adult | 2016 |
Intravenous versus oral dexamethasone for prophylaxis of paclitaxel-associated hypersensitivity reaction in patients with primary ovarian, fallopian tube and peritoneal cancer: A double-blind randomized controlled trial.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Animals; Antineoplastic Agents, Phytogenic; Dexamethasone; Double-Blind Method; Drug Hypersensitivity; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2016 |
High Efficacy and Low Toxicity of the Modified Docetaxel and Carboplatin Protocol in Patients with Recurrent Ovarian Cancer-A Phase 2 Cohort Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Cohort Studies; Cystadenocarcinoma, Serous; Docetaxel; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate; Taxoids | 2016 |
Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Gr
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Analysis | 2016 |
Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Young Adult | 2017 |
A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Chemotherapy, Adjuvant; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2008 |
Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel.
Topics: Adult; Aged; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Cross-Over Studies; Fallopian Tube Neoplasms; Female; Humans; Male; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Solvents | 2008 |
Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Drug Interactions; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyglutamic Acid | 2008 |
A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyglutamic Acid | 2008 |
Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Disease-Free Survival; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Genital Neoplasms, Female; Humans; Mixed Tumor, Mullerian; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Quality of Life | 2009 |
Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Infusions, Parenteral; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2009 |
Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Middle Aged; Mixed Tumor, Mullerian; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Patient Compliance; Peritoneal Neoplasms | 2009 |
Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents, Phytogenic; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quality of Life | 2009 |
Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Risk Factors; Taxoids; Treatment Outcome; Young Adult | 2009 |
Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Gefitinib; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines | 2010 |
A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Polyethylene Glycols; Recombinant Proteins | 2010 |
Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Fallopian Tube Neoplasms; Female; Gene Amplification; Genes, erbB-1; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines; Young Adult | 2010 |
A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Young Adult | 2011 |
Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Isoflavones; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum Compounds; Taxoids; Treatment Failure; Treatment Outcome | 2011 |
A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Albumins; Antineoplastic Agents, Phytogenic; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Nanoparticles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2011 |
Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheterization; Cisplatin; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2011 |
Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2011 |
Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Induction Chemotherapy; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Young Adult | 2011 |
Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Drug Administration Schedule; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2012 |
A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncol
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2012 |
Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Double-Blind Method; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Recombinant Fusion Proteins; Survival Analysis | 2012 |
Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Injections, Intraperitoneal; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Pemetrexed; Peritoneal Neoplasms; Prognosis; Survival Rate; Tissue Distribution | 2012 |
A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2012 |
Increased incidence of severe gastrointestinal events with first-line paclitaxel, carboplatin, and vorinostat chemotherapy for advanced-stage epithelial ovarian, primary peritoneal, and fallopian tube cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Hydroxamic Acids; Incidence; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Survival Rate; Vorinostat | 2013 |
Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: a Southwest Oncology Group trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2003 |
Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2003 |
Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel | 2003 |
Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2004 |
A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Lung; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2004 |
Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects | 2004 |
Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyglutamic Acid; Taxoids | 2004 |
Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Mixed Tumor, Mullerian; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan | 2006 |
Paclitaxel and carboplatin therapy in stage I fallopian tube carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Second-Look Surgery | 2006 |
Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols | 2007 |
Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Analysis | 2007 |
Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Peritoneal Neoplasms | 2008 |
[A clinical report of refractory carcinoma of ovary and fallopian tube treated with taxol].
Topics: Adenocarcinoma; Adult; Aged; Cystadenocarcinoma, Serous; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Remission Induction | 1995 |
Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Infusions, Parenteral; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects | 1995 |
Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Salvage Therapy; Treatment Failure | 1998 |
Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Fallopian Tube Neoplasms; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate | 1998 |
Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carboplatin; Cisplatin; Cystadenocarcinoma, Papillary; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Ifosfamide; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 1998 |
Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Statistics, Nonparametric; Survival Analysis; Taxoids | 2000 |
Phase I study of paclitaxel, carboplatin, and increasing days of prolonged oral etoposide in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Etoposide; Fallopian Tube Neoplasms; Female; Humans; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Thrombocytopenia | 2000 |
Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Doxorubicin; Drug Carriers; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Erythema; Fallopian Tube Neoplasms; Female; Foot Dermatoses; Hand Dermatoses; Humans; Liposomes; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Stomatitis; Stroke Volume | 2000 |
Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; CA-125 Antigen; Carboplatin; Cisplatin; Drug Administration Schedule; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan | 2000 |
Paclitaxel-based chemotherapy in carcinoma of the fallopian tube.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Survival Rate | 2001 |
Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Docetaxel; Drug Hypersensitivity; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2001 |
Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study.
Topics: Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Carboplatin; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan | 2001 |
A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Liposomes; Middle Aged; Mixed Tumor, Mullerian; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2002 |
A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.
Topics: Adenoviridae; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; CA-125 Antigen; Carboplatin; Cohort Studies; Combined Modality Therapy; DNA, Viral; Enzyme-Linked Immunosorbent Assay; Fallopian Tube Neoplasms; Female; Genes, p53; Genetic Therapy; Humans; Mutation; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Tomography, X-Ray Computed; Transgenes | 2002 |
69 other study(ies) available for paclitaxel and Cancer of the Fallopian Tube
| Article | Year |
|---|---|
Prospective feasibility study of neoadjuvant dose-dense paclitaxel plus carboplatin with bevacizumab therapy followed by interval debulking surgery for advanced ovarian, fallopian tube, and primary peritoneal cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cytoreduction Surgical Procedures; Fallopian Tube Neoplasms; Fallopian Tubes; Feasibility Studies; Female; Humans; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Prospective Studies | 2022 |
Dose-dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Peritoneal Neoplasms; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies | 2020 |
A simple method of quantifying chemotherapy-induced peripheral neuropathy using PainVision PS-2100
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Fallopian Tube Neoplasms; Female; Humans; Incidence; Japan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pain; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Pilot Projects; Risk Assessment; Risk Factors; Skin; Young Adult | 2020 |
Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study.
Topics: Adult; Aged; Carboplatin; Cohort Studies; Doxorubicin; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols; Progression-Free Survival; Republic of Korea; Retrospective Studies | 2020 |
Responses of metastatic primary fallopian tube carcinoma to pembrolizumab and nab-paclitaxel: A case report.
Topics: Adult; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Fallopian Tube Neoplasms; Female; Humans; Paclitaxel | 2020 |
Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for BRCA1/2-associated breast cancer: a case report.
Topics: BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Unknown Primary; Paclitaxel; Salpingo-oophorectomy | 2021 |
Prognostic Benefit of ≥6 Cycles of Neoadjuvant Chemotherapy for Advanced Ovarian, Tubal, and Peritoneal Cancers.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Fallopian Tube Neoplasms; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies | 2021 |
Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cohort Studies; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 2017 |
Poor Prognostic Factors in Patients Undergoing Surgery After Neoadjuvant Chemotherapy for Ovarian, Tubal, or Peritoneal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Turkey | 2017 |
Efficacy and safety of dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube or peritoneal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies | 2017 |
The Prognostic Impact of the Pathological Response to Neoadjuvant Dose-Dense Therapy for Ovarian Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies | 2017 |
Efficacy of weekly administration of paclitaxel and carboplatin for advanced ovarian cancer patients with poor performance status.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2018 |
Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Fallopian Tube Neoplasms; Female; Humans; Length of Stay; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Postoperative Complications; Survival Rate; Time Factors | 2018 |
Prognostic implications of histological tumor regression (Böhm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Chemotherapy, Adjuvant; Cohort Studies; Cystadenocarcinoma, Serous; Fallopian Tube Neoplasms; Female; Humans; Membrane Proteins; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Regression Analysis; Retrospective Studies; Survival Rate | 2018 |
Management of epithelial cancer of the ovary, fallopian tube, primary peritoneum. Long text of the joint French clinical practice guidelines issued by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY, endorsed by INCa. (Part 2: systemic, intraperitoneal treatment, e
Topics: Adult; Aged; Aged, 80 and over; Bevacizumab; Carboplatin; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Female; Fertility Preservation; France; Humans; Hyperthermia, Induced; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2019 |
Morbidity after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with carboplatin used for ovarian, tubal, and primary peritoneal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Fallopian Tube Neoplasms; Female; Humans; Hyperthermia, Induced; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies | 2019 |
Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Drug Administration Schedule; Drug Tolerance; Fallopian Tube Neoplasms; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome | 2013 |
Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Phosphatidylcholines; Polyethylene Glycols; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
Safety and outcome of patients treated with a modified outpatient intraperitoneal regimen for epithelial ovarian, primary peritoneal or fallopian tube cancer.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Middle Aged; Neoplasm Staging; Neoplasms, Multiple Primary; Outpatients; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Treatment Outcome | 2013 |
Survival and prognostic factors of patients with primary fallopian tube cancer receiving adjuvant paclitaxel and carboplatin chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cohort Studies; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Hospitals, University; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Analysis; Thailand | 2014 |
Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Genes, BRCA1; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Prognosis; Proportional Hazards Models | 2015 |
Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Hysterectomy; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Omentum; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Predictive Value of Tests; Prognosis; Reproducibility of Results; Salpingectomy; Treatment Outcome | 2015 |
Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cohort Studies; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Severity of Illness Index; Survival Rate; Treatment Outcome | 2015 |
Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Cytoreduction Surgical Procedures; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Injections, Intraperitoneal; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Propensity Score; Prospective Studies; Treatment Outcome | 2016 |
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for gynecological malignancies: a single center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cohort Studies; Cytoreduction Surgical Procedures; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Sarcoma; Survival Rate; Treatment Outcome; Uterine Neoplasms; Young Adult | 2016 |
Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Docetaxel; Fallopian Tube Neoplasms; Female; Guideline Adherence; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Taxoids | 2016 |
Investigating the Impact of Body Mass Index on Intraperitoneal Chemotherapy Outcomes in Ovarian and Fallopian Tube Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Body Mass Index; Carboplatin; Cisplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Treatment Outcome | 2016 |
Feasibility of dose-dense paclitaxel/carboplatin therapy in elderly patients with ovarian, fallopian tube, or peritoneal cancer.
Topics: Adult; Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Male; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Analysis | 2016 |
Dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies | 2016 |
Reversible posterior leukoencephalopathy syndrome following intravenous paclitaxel and intraperitoneal cisplatin chemotherapy for fallopian tube cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Paclitaxel; Posterior Leukoencephalopathy Syndrome | 2008 |
Paclitaxel- and platinum-based postoperative chemotherapy for primary fallopian tube carcinoma: a single institution experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Platinum Compounds; Retrospective Studies; Survival Analysis; Treatment Outcome | 2008 |
Chemotherapy consisting of paclitaxel and carboplatin benefits a patient with malignant mixed müllerian tumor of the fallopian tube.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Fallopian Tube Neoplasms; Female; Humans; Mixed Tumor, Mullerian; Ovariectomy; Paclitaxel | 2008 |
An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
Topics: Adenocarcinoma; Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Fallopian Tube Neoplasms; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Outpatients; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Retrospective Studies | 2009 |
Outcomes associated with different intraperitoneal chemotherapy delivery systems in advanced ovarian carcinoma: a single institution's experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Cisplatin; Fallopian Tube Neoplasms; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2009 |
Primary fallopian tube carcinoma: results of a retrospective analysis of 64 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Treatment Outcome | 2009 |
Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Databases, Factual; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epithelial Cells; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies | 2010 |
Cancer-associated retinopathy in neuroendocrine carcinoma of the fallopian tube.
Topics: Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Neuroendocrine; Fallopian Tube Neoplasms; Female; Humans; Paclitaxel; Positron-Emission Tomography; Retinal Diseases; Visual Acuity; Visual Fields | 2010 |
Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Brachytherapy; Brain Neoplasms; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Combined Modality Therapy; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Risk Factors; Survival Rate; Taxoids; Treatment Outcome | 2011 |
A randomized Phase II/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Japan; Ovarian Neoplasms; Paclitaxel; Patient Selection; Peritoneal Neoplasms; Randomized Controlled Trials as Topic; Research Design | 2011 |
Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; CA-125 Antigen; Carcinoma; Carcinoma, Ovarian Epithelial; Cisplatin; Cytotoxins; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Immunoenzyme Techniques; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Protein Serine-Threonine Kinases; Receptor, Transforming Growth Factor-beta Type I; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Transforming Growth Factor beta1 | 2011 |
Second-line chemotherapy with docetaxel and carboplatin in paclitaxel and platinum-pretreated ovarian, fallopian tube, and peritoneal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Retrospective Studies; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
A pilot study evaluating a novel regimen comprised of carboplatin, paclitaxel, and bevacizumab for advanced-stage ovarian carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Survival Rate; Treatment Outcome | 2010 |
Primary fallopian tube carcinoma: clinicopathological analysis of 12 cases.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Diagnosis, Differential; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Retrospective Studies | 2011 |
Second-line chemotherapy for carboplatin/paclitaxel-refractory ovarian cancer: are multi-agent chemotherapies of little value truly?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2011 |
Feasibility study on biweekly paclitaxel treatment as maintenance chemotherapy in advanced müllerian carcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Endometrioid; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2012 |
Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate | 2012 |
Supplementation with hydrocortisone on the 3rd-5th day following dexamethasone premedicated chemotherapy eliminated severe dizziness and postural hypotension.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dexamethasone; Dizziness; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Humans; Hydrocortisone; Hypotension, Orthostatic; Middle Aged; Paclitaxel; Premedication; Time Factors | 2012 |
Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2012 |
Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Kaplan-Meier Estimate; Lymph Node Excision; Middle Aged; Neoplasm Grading; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Pelvis; Peritoneal Neoplasms; Proportional Hazards Models; Retrospective Studies | 2012 |
Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Injections, Intraperitoneal; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies | 2012 |
Stage III malignant mixed Müllerian tumor of the fallopian tube: a case of 5-year survival after optimal debulking and adjuvant chemotherapy with paclitaxel plus carboplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Mixed Tumor, Mullerian; Paclitaxel | 2012 |
Prognostic significance of rising serum CA-125 levels within the normal range in patients with epithelial ovarian, primary peritoneal, and tubal cancers, who, after initial treatment, had a complete clinical response.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate | 2012 |
Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate | 2013 |
Dose-dense paclitaxel with carboplatin for advanced ovarian cancer: a feasible treatment alternative.
Topics: Alberta; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Recombinant Proteins; Survival Rate | 2013 |
Effects of Taxol on ascites cytology from a patient with fallopian tube carcinoma: report of a case with ultrastructural studies.
Topics: Antineoplastic Agents, Phytogenic; Ascites; Cystadenocarcinoma, Serous; Fallopian Tube Neoplasms; Female; Humans; Microscopy, Electron; Middle Aged; Mitosis; Paclitaxel; Pleural Effusion | 2002 |
Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carboplatin; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2003 |
Adverse affects of paclitaxel and carboplatin combination chemotherapy in epithelial gynecologic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cross-Sectional Studies; Fallopian Tube Neoplasms; Female; Genital Neoplasms, Female; Hematologic Diseases; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2005 |
A pilot study of weekly docetaxel therapy for recurrent ovarian cancer, tubal cancer, and primary peritoneal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; CA-125 Antigen; Docetaxel; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Platinum Compounds; Taxoids; Treatment Outcome | 2005 |
Aggressive multimodality treatment in transitional cell carcinoma of the parafallopian tube: report of 2 cases and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel | 2006 |
Case records of the Massachusetts General Hospital. Case 11-2006. A 54-year-old woman with a mass in the pelvis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Combined Modality Therapy; Cystadenocarcinoma, Papillary; Diagnosis, Differential; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Paclitaxel; Tomography, X-Ray Computed | 2006 |
Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2008 |
[Analysis of therapeutic result and prognostic factor in primary fallopian tube carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Papillary; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Hysterectomy; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Ovariectomy; Paclitaxel; Survival Rate; Taxoids | 2007 |
Primary fallopian tube adenocarcinoma: clinical complete response after salvage treatment with high-dose paclitaxel.
Topics: Adenocarcinoma; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Salvage Therapy | 1995 |
Primary carcinoma of the fallopian tube: report on two cases.
Topics: Adenocarcinoma; Adenocarcinoma, Papillary; CA-125 Antigen; Cisplatin; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Paclitaxel | 1996 |
Recurrent metastatic fallopian tube carcinoma in pregnancy.
Topics: Abdominal Neoplasms; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fallopian Tube Neoplasms; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Salvage Therapy | 2001 |
Experience at the Memorial Sloan-Kettering Cancer Center with paclitaxel-based combination chemotherapy following primary cytoreductive surgery in carcinoma of the fallopian tube.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fallopian Tube Neoplasms; Female; Humans; Paclitaxel | 2002 |
[Clinical observation of palitaxel in the treatment of gynecologic malignant tumors].
Topics: Adult; Antineoplastic Agents; Cisplatin; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2000 |
Brain metastases from fallopian tube carcinoma responsive to intra-arterial carboplatin and intravenous etoposide: a case report.
Topics: Adenocarcinoma, Papillary; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brain Stem; Carboplatin; Carotid Arteries; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Dacarbazine; Etoposide; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Magnetic Resonance Imaging; Middle Aged; Paclitaxel; Physical Examination; Rupture, Spontaneous; Temozolomide; Temporal Lobe; Vertebral Artery | 2001 |